New cancer drug copycat tested in healthy people
NCT ID NCT03881787
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new drug called CDP1, which is a close copy of the cancer drug Erbitux, in 84 healthy male volunteers. The goal was to see how the body handles CDP1, whether it causes side effects, and if it triggers an immune response. The results will help decide if CDP1 can move into larger studies in cancer patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anti-EGFR monoclonal antibody (CDP1)
- What this could lead to
- If successful, this could support CDP1 as a more affordable alternative to Erbitux for treating certain cancers.
- What could go wrong
- This is an early-phase trial in healthy people, not patients. It only checks safety and drug levels, not whether it works against cancer. The drug may still fail in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
-
West China Hospital
Chengdu, Sichuang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults